AG˹ٷ

STOCK TITAN

[Form 4] SeaStar Medical Holding Corporation Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

On July 1, 2025, SeaStar Medical Holding Corporation (ICU) Chief Medical Officer Kevin Chung filed a Form 4 disclosing the vesting and conversion of 5,000 restricted stock units (RSUs) into common shares. The transaction was coded “M,� signifying a conversion of derivative equity awards rather than an open-market purchase, and carried a price of $0 per share.

After the transaction, Dr. Chung now directly owns 48,184 ICU shares. This figure incorporates 25,000 shares that were previously reported as unvested RSUs in Table II and have been moved to Table I. The filing also corrects a prior one-share rounding error, and no derivative RSUs remain reportable from this grant.

The RSUs originated from a November 15, 2024 grant of 15,000 units that vest in three equal annual tranches beginning July 1, 2024; the current filing reflects the first installment. Because the shares were received under a pre-arranged compensation plan at no cost, the event does not inject new capital into the company nor constitute an open-market confidence signal. Nevertheless, it modestly increases insider equity alignment and provides transparency regarding executive compensation.

Il 1° luglio 2025, il Chief Medical Officer di SeaStar Medical Holding Corporation (ICU), Kevin Chung, ha presentato un modulo Form 4 per comunicare la maturazione e conversione di 5.000 unità azionarie vincolate (RSU) in azioni ordinarie. L'operazione è stata codificata come “M�, indicando una conversione di premi azionari derivati e non un acquisto sul mercato aperto, con un prezzo pari a 0 dollari per azione.

Dopo l'operazione, il dottor Chung detiene direttamente 48.184 azioni ICU. Questa cifra include 25.000 azioni precedentemente segnalate come RSU non maturate nella Tabella II, ora spostate nella Tabella I. La comunicazione corregge inoltre un errore di arrotondamento di una singola azione e non rimangono RSU derivati da segnalare per questa concessione.

Le RSU derivano da una concessione del 15 novembre 2024 di 15.000 unità che maturano in tre tranche annuali uguali a partire dal 1° luglio 2024; la presente comunicazione riflette la prima tranche. Poiché le azioni sono state ricevute nell'ambito di un piano di compensazione predefinito senza alcun costo, l'evento non comporta l'immissione di nuovo capitale nella società né rappresenta un segnale di fiducia sul mercato aperto. Tuttavia, aumenta modestamente l'allineamento azionario degli insider e garantisce trasparenza riguardo alla remunerazione degli executive.

El 1 de julio de 2025, el Director Médico de SeaStar Medical Holding Corporation (ICU), Kevin Chung, presentó un Formulario 4 revelando la consolidación y conversión de 5.000 unidades restringidas de acciones (RSU) en acciones ordinarias. La transacción fue codificada como “M�, lo que indica una conversión de premios derivados de acciones y no una compra en el mercado abierto, con un precio de 0 dólares por acción.

Tras la operación, el Dr. Chung posee directamente 48.184 acciones de ICU. Esta cifra incluye 25.000 acciones que previamente se reportaron como RSU no consolidadas en la Tabla II y que han sido trasladadas a la Tabla I. Además, la presentación corrige un error de redondeo de una acción anterior y no quedan RSU derivados pendientes de reporte de esta concesión.

Las RSU provienen de una concesión del 15 de noviembre de 2024 de 15.000 unidades que se consolidan en tres partes iguales anuales a partir del 1 de julio de 2024; esta presentación refleja la primera cuota. Dado que las acciones se recibieron bajo un plan de compensación preestablecido sin costo alguno, el evento no inyecta nuevo capital en la empresa ni constituye una señal de confianza en el mercado abierto. Sin embargo, incrementa modestamente la alineación accionarial interna y aporta transparencia respecto a la compensación ejecutiva.

2025� 7� 1�, SeaStar Medical Holding Corporation (ICU)� 최고 의료 책임� 케� �(Kevin Chung)� 5,000개의 제한 주식 단위(RSU)� 권리 취득 � 보통� 전환� 공시하는 Form 4� 제출했습니다. 해당 거래� 파생 주식 보상 전환� 의미하는 “M� 코드� 표시되었으며, 주당 가격은 0달러였습니�.

거래 � � 박사� 직접 48,184� ICU 주식� 보유하게 되었습니�. � 수치에는 이전� 미권� RSU� II표에 보고되었� 25,000�가 포함되어 있으�, I표로 이동되었습니�. 또한 이번 제출은 이전� 1� 반올� 오류� 수정하며, � 보조금에� 보고� 파생 RSU� 남아있지 않습니다.

� RSU� 2024� 11� 15일에 부여된 15,000단위�, 2024� 7� 1일부� 3년에 걸쳐 동일� 비율� 권리가 부여됩니다. 이번 제출은 � 번째 분할분을 반영합니�. 주식� 사전 합의� 보상 계획� 따라 무상으로 수령되었� 때문�, 이번 사건은 회사� 새로� 자본� 투입하지 않으� 공개 시장에서� 신뢰 신호� 아닙니다. 그럼에도 불구하고 내부� 지� 정렬� 다소 높이� 경영� 보상� 대� 투명성을 제공합니�.

Le 1er juillet 2025, le directeur médical de SeaStar Medical Holding Corporation (ICU), Kevin Chung, a déposé un formulaire 4 divulguant la maturation et conversion de 5 000 unités d'actions restreintes (RSU) en actions ordinaires. La transaction a été codée « M », indiquant une conversion d'attributions d'actions dérivées plutôt qu'un achat sur le marché ouvert, avec un prix de 0 $ par action.

Après la transaction, le Dr Chung détient désormais directement 48 184 actions ICU. Ce chiffre inclut 25 000 actions qui étaient précédemment déclarées comme des RSU non acquises dans le Tableau II et qui ont été déplacées au Tableau I. Le dépôt corrige également une erreur d'arrondi d'une action antérieure, et il ne reste plus de RSU dérivées à déclarer pour cette attribution.

Les RSU proviennent d'une attribution du 15 novembre 2024 de 15 000 unités qui acquièrent leurs droits en trois tranches annuelles égales à partir du 1er juillet 2024 ; le dépôt actuel reflète la première tranche. Étant donné que les actions ont été reçues dans le cadre d'un plan de rémunération préétabli sans coût, cet événement n'injecte pas de nouveau capital dans l'entreprise ni ne constitue un signal de confiance sur le marché ouvert. Néanmoins, il augmente modestement l'alignement des intérêts des initiés et apporte de la transparence concernant la rémunération des dirigeants.

Am 1. Juli 2025 reichte der Chief Medical Officer von SeaStar Medical Holding Corporation (ICU), Kevin Chung, ein Formular 4 ein, in dem die Vesting und Umwandlung von 5.000 Restricted Stock Units (RSUs) in Stammaktien offengelegt wurden. Die Transaktion wurde mit „M� codiert, was eine Umwandlung von derivativen Aktienprämien und keinen Kauf am offenen Markt bedeutet, und hatte einen Preis von 0 USD pro Aktie.

Nach der Transaktion besitzt Dr. Chung nun direkt 48.184 ICU-Aktien. Diese Zahl beinhaltet 25.000 Aktien, die zuvor als nicht vestete RSUs in Tabelle II gemeldet wurden und nun in Tabelle I verschoben wurden. Die Meldung korrigiert zudem einen vorherigen Rundungsfehler von einer Aktie, und es verbleiben keine berichtspflichtigen derivativen RSUs aus dieser Zuteilung.

Die RSUs stammen aus einer Zuteilung vom 15. November 2024 über 15.000 Einheiten, die in drei gleichen jährlichen Tranchen ab dem 1. Juli 2024 vesten; die aktuelle Meldung spiegelt die erste Tranche wider. Da die Aktien im Rahmen eines vorab vereinbarten Vergütungsplans ohne Kosten erhalten wurden, führt das Ereignis nicht zu einer Kapitalzufuhr in das Unternehmen und stellt kein Vertrauenssignal am offenen Markt dar. Dennoch erhöht es moderat die interne Aktionärsausrichtung und sorgt für Transparenz bei der Vergütung der Führungskräfte.

Positive
  • Insider ownership increased to 48,184 shares, modestly strengthening management–shareholder alignment.
Negative
  • None.

Insights

TL;DR: Routine RSU vesting; minimal direct market impact.

The filing simply records the first tranche of a previously granted RSU award. Although it boosts Chung’s direct stake to 48,184 shares, the stock was acquired at no cost and does not represent an open-market buy. From a valuation standpoint, the transaction is neutral: it neither alters SeaStar Medical’s cash position nor signals management’s view on current pricing. Investors may view the increased ownership as incremental alignment, but the absolute share count is unlikely to sway the investment thesis given the company’s overall float.

TL;DR: Proper Section 16 reporting; alignment incrementally improved.

The Form 4 is timely and complete, demonstrating compliance with Section 16(a) obligations. Moving previously unvested RSUs into Table I clarifies ownership and enhances disclosure accuracy. While the vesting is standard under the firm’s 2024 equity plan, the absence of remaining derivative units for this grant indicates transparent bookkeeping. Governance watchers may note the small but positive shift in insider-shareholder alignment.

Il 1° luglio 2025, il Chief Medical Officer di SeaStar Medical Holding Corporation (ICU), Kevin Chung, ha presentato un modulo Form 4 per comunicare la maturazione e conversione di 5.000 unità azionarie vincolate (RSU) in azioni ordinarie. L'operazione è stata codificata come “M�, indicando una conversione di premi azionari derivati e non un acquisto sul mercato aperto, con un prezzo pari a 0 dollari per azione.

Dopo l'operazione, il dottor Chung detiene direttamente 48.184 azioni ICU. Questa cifra include 25.000 azioni precedentemente segnalate come RSU non maturate nella Tabella II, ora spostate nella Tabella I. La comunicazione corregge inoltre un errore di arrotondamento di una singola azione e non rimangono RSU derivati da segnalare per questa concessione.

Le RSU derivano da una concessione del 15 novembre 2024 di 15.000 unità che maturano in tre tranche annuali uguali a partire dal 1° luglio 2024; la presente comunicazione riflette la prima tranche. Poiché le azioni sono state ricevute nell'ambito di un piano di compensazione predefinito senza alcun costo, l'evento non comporta l'immissione di nuovo capitale nella società né rappresenta un segnale di fiducia sul mercato aperto. Tuttavia, aumenta modestamente l'allineamento azionario degli insider e garantisce trasparenza riguardo alla remunerazione degli executive.

El 1 de julio de 2025, el Director Médico de SeaStar Medical Holding Corporation (ICU), Kevin Chung, presentó un Formulario 4 revelando la consolidación y conversión de 5.000 unidades restringidas de acciones (RSU) en acciones ordinarias. La transacción fue codificada como “M�, lo que indica una conversión de premios derivados de acciones y no una compra en el mercado abierto, con un precio de 0 dólares por acción.

Tras la operación, el Dr. Chung posee directamente 48.184 acciones de ICU. Esta cifra incluye 25.000 acciones que previamente se reportaron como RSU no consolidadas en la Tabla II y que han sido trasladadas a la Tabla I. Además, la presentación corrige un error de redondeo de una acción anterior y no quedan RSU derivados pendientes de reporte de esta concesión.

Las RSU provienen de una concesión del 15 de noviembre de 2024 de 15.000 unidades que se consolidan en tres partes iguales anuales a partir del 1 de julio de 2024; esta presentación refleja la primera cuota. Dado que las acciones se recibieron bajo un plan de compensación preestablecido sin costo alguno, el evento no inyecta nuevo capital en la empresa ni constituye una señal de confianza en el mercado abierto. Sin embargo, incrementa modestamente la alineación accionarial interna y aporta transparencia respecto a la compensación ejecutiva.

2025� 7� 1�, SeaStar Medical Holding Corporation (ICU)� 최고 의료 책임� 케� �(Kevin Chung)� 5,000개의 제한 주식 단위(RSU)� 권리 취득 � 보통� 전환� 공시하는 Form 4� 제출했습니다. 해당 거래� 파생 주식 보상 전환� 의미하는 “M� 코드� 표시되었으며, 주당 가격은 0달러였습니�.

거래 � � 박사� 직접 48,184� ICU 주식� 보유하게 되었습니�. � 수치에는 이전� 미권� RSU� II표에 보고되었� 25,000�가 포함되어 있으�, I표로 이동되었습니�. 또한 이번 제출은 이전� 1� 반올� 오류� 수정하며, � 보조금에� 보고� 파생 RSU� 남아있지 않습니다.

� RSU� 2024� 11� 15일에 부여된 15,000단위�, 2024� 7� 1일부� 3년에 걸쳐 동일� 비율� 권리가 부여됩니다. 이번 제출은 � 번째 분할분을 반영합니�. 주식� 사전 합의� 보상 계획� 따라 무상으로 수령되었� 때문�, 이번 사건은 회사� 새로� 자본� 투입하지 않으� 공개 시장에서� 신뢰 신호� 아닙니다. 그럼에도 불구하고 내부� 지� 정렬� 다소 높이� 경영� 보상� 대� 투명성을 제공합니�.

Le 1er juillet 2025, le directeur médical de SeaStar Medical Holding Corporation (ICU), Kevin Chung, a déposé un formulaire 4 divulguant la maturation et conversion de 5 000 unités d'actions restreintes (RSU) en actions ordinaires. La transaction a été codée « M », indiquant une conversion d'attributions d'actions dérivées plutôt qu'un achat sur le marché ouvert, avec un prix de 0 $ par action.

Après la transaction, le Dr Chung détient désormais directement 48 184 actions ICU. Ce chiffre inclut 25 000 actions qui étaient précédemment déclarées comme des RSU non acquises dans le Tableau II et qui ont été déplacées au Tableau I. Le dépôt corrige également une erreur d'arrondi d'une action antérieure, et il ne reste plus de RSU dérivées à déclarer pour cette attribution.

Les RSU proviennent d'une attribution du 15 novembre 2024 de 15 000 unités qui acquièrent leurs droits en trois tranches annuelles égales à partir du 1er juillet 2024 ; le dépôt actuel reflète la première tranche. Étant donné que les actions ont été reçues dans le cadre d'un plan de rémunération préétabli sans coût, cet événement n'injecte pas de nouveau capital dans l'entreprise ni ne constitue un signal de confiance sur le marché ouvert. Néanmoins, il augmente modestement l'alignement des intérêts des initiés et apporte de la transparence concernant la rémunération des dirigeants.

Am 1. Juli 2025 reichte der Chief Medical Officer von SeaStar Medical Holding Corporation (ICU), Kevin Chung, ein Formular 4 ein, in dem die Vesting und Umwandlung von 5.000 Restricted Stock Units (RSUs) in Stammaktien offengelegt wurden. Die Transaktion wurde mit „M� codiert, was eine Umwandlung von derivativen Aktienprämien und keinen Kauf am offenen Markt bedeutet, und hatte einen Preis von 0 USD pro Aktie.

Nach der Transaktion besitzt Dr. Chung nun direkt 48.184 ICU-Aktien. Diese Zahl beinhaltet 25.000 Aktien, die zuvor als nicht vestete RSUs in Tabelle II gemeldet wurden und nun in Tabelle I verschoben wurden. Die Meldung korrigiert zudem einen vorherigen Rundungsfehler von einer Aktie, und es verbleiben keine berichtspflichtigen derivativen RSUs aus dieser Zuteilung.

Die RSUs stammen aus einer Zuteilung vom 15. November 2024 über 15.000 Einheiten, die in drei gleichen jährlichen Tranchen ab dem 1. Juli 2024 vesten; die aktuelle Meldung spiegelt die erste Tranche wider. Da die Aktien im Rahmen eines vorab vereinbarten Vergütungsplans ohne Kosten erhalten wurden, führt das Ereignis nicht zu einer Kapitalzufuhr in das Unternehmen und stellt kein Vertrauenssignal am offenen Markt dar. Dennoch erhöht es moderat die interne Aktionärsausrichtung und sorgt für Transparenz bei der Vergütung der Führungskräfte.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Chung Kevin

(Last) (First) (Middle)
C/O SEASTAR MEDICAL HOLDING CORPORATION
3513 BRIGHTON BLVD., SUITE 410

(Street)
DENVER CO 80216

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SeaStar Medical Holding Corp [ ICU ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Medical Officer
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.0001 per share(1) 07/01/2025 M 5,000(2) A $0 48,184(3)(4) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (5) 07/01/2025 M 5,000 (6) (6) Common Stock, par value $0.0001 per share 5,000 $0 0(7) D
Explanation of Responses:
1. This Form 4 is being filed to report the vesting of certain restricted stock unit ("RSU") awards and the moving of unvested RSU awards previously reported in Table II to Table I.
2. Reflects RSUs that upon vesting converted into shares of ICU common stock.
3. The total includes 25,000 shares underlying RSUs that were previously reported in Table II.
4. Reflects a reduction by one share to correct a previous rounding error.
5. Each restricted stock unit represents a contingent right to receive one share of ICU common stock.
6. As previously reported, on November 15, 2024, the reporting person was granted 15,000 RSUs, vesting in three equal annual installments on the first, second and third anniversaries of July 1, 2024.
7. The total does not include 25,000 shares underlying RSUs that are now reported in Table I.
Remarks:
/s/ David A. Green, as attorney-in-fact 07/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did SeaStar Medical (ICU) disclose in the July 1 2025 Form 4?

The company reported that CMO Kevin Chung’s 5,000 RSUs vested and converted into common shares.

How many ICU shares does Kevin Chung own after the transaction?

Following the RSU conversion, he directly holds 48,184 shares of ICU common stock.

What does transaction code "M" mean on a Form 4?

Code “M� indicates the conversion of a derivative security, such as an RSU, into common stock.

Were any derivative securities left after the RSU conversion?

No. The filing shows 0 derivative RSUs remaining from this grant.

Did Kevin Chung pay for the shares he received?

No. The RSUs converted at a price of $0 per share under the company’s equity compensation plan.
SeaStar Medical Holding Corp

NASDAQ:ICU

ICU Rankings

ICU Latest News

ICU Latest SEC Filings

ICU Stock Data

6.78M
17.23M
2.09%
2.07%
4.1%
Biotechnology
Surgical & Medical Instruments & Apparatus
United States
DENVER